Retrospective database analysis on the effectiveness of typical and atypical antipsychotic drugs in an outpatient clinic setting

Human Psychopharmacology

Volumn 22, Issue 8, 2007, Pages 515-528

  Akkaya, Cengiz ^a   Sarandol, Asli ^a   Cangur, Sengul ^a   Kirli, Selcuk ^a  

^a ULUDAG UNIVERSITY   (Turkey)

Author keywords

Antipsychotic treatment; Database analysis; Effectiveness; Schizophrenia

Indexed keywords

AMISULPRIDE; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CARBAMAZEPINE; CHLORPROMAZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; FLUPENTIXOL; FLUPHENAZINE; HALOPERIDOL; LITHIUM SALT; LONG ACTING DRUG; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; PIMOZIDE; QUETIAPINE; RISPERIDONE; SULPRIDE; THIORIDAZINE; TRANQUILIZER; TRIFLUOPERAZINE; UNCLASSIFIED DRUG; VALPROIC ACID; ZUCLOPENTHIXOL;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DEMOGRAPHY; DRUG EFFICACY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYNDROME; FEMALE; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NAUSEA AND VOMITING; OUTPATIENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SOCIAL ASPECT; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; TREATMENT OUTCOME; WEIGHT GAIN;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DATABASES, FACTUAL; FEMALE; HALOPERIDOL; HOSPITALS, UNIVERSITY; HUMANS; LONG-TERM CARE; MALE; MIDDLE AGED; OUTPATIENT CLINICS, HOSPITAL; RETROSPECTIVE STUDIES; RISPERIDONE; SCHIZOPHRENIA; TREATMENT OUTCOME; TREATMENT REFUSAL; TURKEY;

EID: 37849005650     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.882     Document Type: Article

References (47)

1. American Psychiatric Association. 1994. Diagnostic and Statistical Manual of Mental Disorders (4th edn). American Psychiatric Association: Washington, DC.
2. Ascher-Svanum H, Zhu B, Faries D, Landbloom R, Swartz M, Swanson J. 2006. Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia. BMC Psychiatr 6: 8.
3. Barton S. 2000. Which clinical studies provide the best evidence? The best RCT still trumps the best observational study. BMJ 321: 255-256.
4. Benson K, Hartz AJ. 2000. A comparison of observational studies and randomized, controlled trials. N Engl J Med 342: 1878-1886.
5. Britton A, McKee M, Black N, McPherson K, Sanderson C, Bain C. 1998. Choosing between randomised and non-randomised studies: a systematic review. Health Technol Assess 2: 1-124.
6. Caine ED. 2006. Clinical perspectives on atypical antipsychotics for treatment of agitation. J Clin Psychiatr 67 (Suppl. 10): S22-S31.
7. Concato J, Shah N, Horwitz RI. 2000. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 342: 1887-1892.
8. Conley RR, Love RC, Kelly DL, Bartko JJ. 1999. Rehospitalization rates of patients recently discharged on a regimen of risperidone or clozapine. Am J Psychiatr 156: 863-868.
9. Cramer JA, Rosenheck R. 1998. Compliance with medication regimens for mental and physical disorders. Psychiatr Serv 49: 196-201.
10. Csernansky JG, Schuchart EK. 2002. Relapse and rehospitalisation rates in patients with schizophrenia: effects of second generation antipsychotics. CNS Drugs 16: 473-484.
11. Davis JM, Chen N, Glick ID. 2003. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatr 60: 553-564.
12. Day S. 1999. Dictionary for Clinical Trials. Wiley: Chichester.
13. Gaebel W. 1997. Towards the improvement of compliance: the significance of psycho-education and new antipsychotic drugs. Int Clin Psychopharmacol 12 (Suppl. 1): S37-S42.
14. Gartlehner G, Hansen RA, Nissman D, Lohr KN, Carey TS. 2006. Criteria for distinguishing effectiveness from efficacy trials in systematic reviews. AHRQ Publication No. 06-0046. At http://www.ahrq.gov/downloads/ pub/evidence/pdf/efftrials/efftrials.pdf
15. Gorwood P. 2006. Meeting everyday challenges: antipsychotic therapy in the real world. Eur Neuropsychopharmacol 16 (Suppl. 3): S156-S162.
16. Hanrahan P, Luchins DJ, Fabian R, Tolley G. 2006. Cost-effectiveness of atypical antipsychotic medications versus conventional medication. Expert Opin Pharmacother 7: 1749-1758.
17. Hofer A, Hummer M, Huber R, Kurz M, Walch T, Fleischhacker WW. 2000. Selection bias in clinical trials with antipsychotics. J Clin Psychopharmacol 20: 699-702.
18. Ioannidis JP, Haidich AB, Lau J. 2001. Any casualties in the clash of randomised and observational evidence? BMJ 322: 879-880.
19. Ito C, Kubota Y, Sato M. 1999. A prospective survey on drug choice for prescriptions for admitted patients with schizophrenia. Psychiatry Clin Neurosci 53 (Suppl.): S35-S40.
20. Kane J, Honigfeld G, Singer J, Meltzer H. 1988. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatr 45: 789-796.
21. Kunz R, Khan KS, Neumayer HH. 2000. Observational studies and randomized trials. N Engl J Med 343: 1194-1197.
22. Lagomasino IT, Dwight-Johnson M, Simpson GM. 2005. Psychopharmacology: the need for effectiveness trials to inform evidence-based psychiatric practice. Psychiatr Serv 56: 649-651.
23. Leucht S, Barnes TR, Kissling W, Engel RR, Correll C, Kane JM. 2003a. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatr 160: 1209-1222.
24. Leucht S, Wahlbeck K, Hamann J, Kissling W. 2003b. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 361: 1581-1589.
25. Levy RH. 1996. Sedation in acute and chronic agitation. Pharmacotherapy 16: S152S-S159.
26. Lieberman JA, Stroup TS, McEvoy JP, et al. 2005. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353: 1209-1223.
27. Luchins DJ. 2006. In the aftermath of CATIE: how should administrators value atypical antipsychotic medications? Adm Policy Ment Health 33: 541-543.
28. McKee M, Britton A, Black N, McPherson K, Sanderson C, Bain C. 1999. Methods in health services research. Interpreting the evidence: choosing between randomised and non-randomised studies. BMJ 319: 312-315.
29. Miyamoto S, Duncan GE, Marx CE, Lieberman JA. 2005. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatr 10: 79-104.
30. Mojtabai R, Lavelle J, Gibson PJ, Bromet EJ. 2003. Atypical antipsychotics in first admission schizophrenia: medication continuation and outcomes. Schizophr Bull 29: 519-530.
31. Möller HJ. 2005. Are the new antipsychotics no better than the classical neuroleptics? The problematic answer from the CATIE study. Eur Arch Psychiatr Clin Neurosci 255: 371-372.
32. Paton C, Lelliott P, Harrington M, Okocha C, Sensky T, Duffett R. 2003. Patterns of antipsychotic and anticholinergic prescribing for hospital inpatients. J Psychopharmacol 17: 223-229.
33. Pocock SJ, Elbourne DR. 2000. Randomized trials or observational tribulations? N Engl J Med 342: 1907-1909.
34. Sacristan JA, Soto J, Galende I, Hylan TR. 1997. A review of methodologies for assessing drug effectiveness and a new proposal: randomised database studies. Clin Ther 19: 1510-1517.
35. Saylan M, Alptekin K, Akdemir A, Tetik E, Korb FA. 2004. The Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) Study: baseline clinical and functional characteristics and antipsychotic use patterns in Turkey. Bull Clin Psychopharmacol 14: 132-142.
36. Schumacher JE, Makela EH, Griffin HR. 2003. Multiple antipsychotic medication prescribing patterns. Ann Pharmacother 37: 951-955.
37. Stroup TS, McEvoy JP, Swartz MS, et al. 2003. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr Bull 29: 15-31.
38. Stroup TS, Lieberman JA, McEvoy JP, et al. 2006. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatr 163: 611-622.
39. Swartz MS, Perkins DO, Stroup TS, McEvoy JP, Nieri JM, Haak DC. 2003. Assessing clinical and functional outcomes in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial. Schizophr Bull 29: 33-43.
40. Tapp A, Wood AE, Secrest L, Erdmann J, Cubberley L, Kilzieh N. 2003. Combination antipsychotic therapy in clinical practice. Psychiatr Serv 54: 55-59.
41. Thieda P, Beard S, Richter A, Kane J. 2003. An economic review of compliance with medication therapy in the treatment of schizophrenia. Psychiatr Serv 54: 508-516.
42. Tiihonen J, Walhbeck K, Lonnqvist J, et al. 2006. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ 333: 224.
43. Tsuang MT. 1999. Observational versus experimental studies: would the results be similar? Psychosom Med 61: 146-147.
44. Wahlbeck K, Tuunainen A, Ahokas A, Leucht S. 2001. Dropout rates in randomised antipsychotic drug trials. Psychopharmacology (Berl) 155: 230-233.
45. Weiden PJ, Kozma C, Grogg A, Locklear J. 2004. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv 55: 886-891.
46. Yildiz M, Cerit C. 2006. Annual cost of treatment for schizophrenia: estimation from a university hospital data in Turkey. Bull Clin Psychopharmacol 16: 239-244.
47. Yildiz A, Sachs GS, Turgay A. 2003. Pharmacological management of agitation in emergency settings. Emerg Med J 20: 339-346.